Background After the discovery of somatic mutations in the tyrosine kinase domain (exons
18–24) of the epidermal growth factor receptor (EGFR) correlating with responses of non …

Introduction Mutations of the epidermal growth factor receptor (EGFR) have been proven to
predict activity of the EGFR-tyrosine kinase inhibitors (EGFR-TKI), gefitinib and erlotinib …

Key “driver” mutations have been discovered in specific subgroups of non-small-cell lung
cancer (NSCLC) patients. Activating mutations in the form of deletions in exon 19 (del 19) or …

Somatic mutations in the epidermal growth factor receptor (EGFR) have been identified in
patients with advanced non–small cell lung cancer who achieve dramatic clinical and …

Therapy targeted against the epidermal growth factor receptor (EGFR) has demonstrated
dramatic tumor responses and favorable clinical outcomes in a select group of non-small …

Background: Non–small-cell lung cancers (NSCLCs) containing EGFR mutations are
exquisitely sensitive to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors …

The targeting of the ATP binding pocket of the epidermal growth factor receptor (EGFR)
tyrosine kinase, by the small molecule drugs gefitinib and erlotinib, represents a promising …

The discovery of mutations in the tyrosine kinase domain of the epidermal growth factor
receptor (EGFR) gene in non-small cell lung cancer (NSCLC) accelerated the research of …

Introduction: Mutation of the epidermal growth factor receptor (EGFR) gene can predict the
efficacy of EGFR-tyrosine kinase inhibitors. Different mutations have been shown to co-occur …

The epidermal growth factor receptor (EGFR) has emerged as an attractive therapeutic
target for patients with non–small-cell lung cancer (NSCLC). However, despite its almost …